Table 2.
Sensitivity and specificity of HPV testing among HIV-positive women across different studies
| References | Country | N | HIV status | Test used | Reference test | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|---|
| Fihrnaber et al91 | South Africa | 1,202 | HIV-positive | HC2 (Qiagen) | Histology (CIN2+) | 92 | 51 |
| Kuhn et al90 | South Africa | 956 | Mixed | HC2 (Qiagen) | Histology (CIN2+) | 94 | 64.4 |
| Chibwesha et al50 | Zambia | 200 | HIV-positive | GeneXpert | Histology (CIN2+) | 88 | 60 |
| Dartell et al92 | Tanzania | 3,603 | Mixed | HC2 (Digene) | Cytology (HSIL+) | 94.2 | 82.8 |
| Chung et al29 | Kenya | 500 | HIV-positive | Enzyme immunoassay | Histology (CIN2+) | 83.6 | 55.7 |
| Adamson et al65 | South Africa | 308 | HIV-positive | Aptima HPV mRNA assay on self-collected samples | HPV mRNA assay on clinician-collected samples | 77.4 | 77.7 |
| Segondy et al26 | South Africa | 943 | HIV-positive | careHPV and INNO-LiPA | Histology (CIN2+) | 93.3 (careHPV) 96.7 (INNO-LiPA) |
57.9 (careHPV) 32.0 (INNO-LiPA) |
| Ngou et al93 | South Africa; Burkina Faso | 160 | HIV-positive | HC2 and INNO-LiPA | Histology (CIN2+) | 88.8 (HC2) 92.5 (INNO-LiPA) |
55.2 32.1 |
Abbreviations: CIN2+, cervical intraepithelial neoplasia grade 2 or worse; HC2, Hybrid Capture 2; HIV, human immunodeficiency virus; HPV, human papillomavirus; HSIL+, high-grade squamous intraepithelial lesion.